key: cord-0788787-48koajnh
authors: Bosch, G.; Posso, M.; Louro, J.; Roman, M.; Porta, M.; Castells, X.; Macia, F.
title: Impact of the COVID-19 pandemic on breast cancer screening indicators in a Spanish population-based program: a cohort study
date: 2022-03-07
journal: nan
DOI: 10.1101/2022.03.04.22271911
sha: 5194f4736b77d57e28cf237e2fe8b4634a2ea4db
doc_id: 788787
cord_uid: 48koajnh

Background:To assess the effect of the COVID-19 pandemic on performance indicators in the population-based breast cancer screening program of Parc de Salut Mar (PSMAR), Barcelona, Spain.Methods:We conducted a before-and-after, quasi-experimental study to evaluate participation, recall, false-positives, cancer detection rate, and cancer characteristics in our screening population from March 2020 to March 2021 compared with the four previous rounds (2012-2019). Using independent logistic regression models, we estimated the adjusted odds ratios (aOR) of each of the performance indicators for the COVID-19 period, controlling by type of screening (prevalent or incident), socioeconomic index, family history of breast cancer, and menopausal status. We analyzed 144,779 observations from 47,571 women.ResultsDuring the COVID-19 period, the odds of participation were 11% lower in first-time invitees (aOR=0.89[95%CI=0.84-0.96]) and in those who had previously participated regularly and irregularly (aOR=0.65 [95%CI=0.61-0.69] and aOR=0.93 [95%CI=0.85-1.03], respectively). Participation showed a modest increase in women not attending any of the previous rounds (aOR=1.07 [95%CI=0.99-1.17]). The recall rate slightly decreased in both prevalent and incident screening (aOR=0.89 [95%CI=0.78-1.01] and aOR=0.89 [95%CI=0.79-1.00], respectively). No significant differences were observed in false-positives (prevalent - aOR=1.07 [95%CI=0.92-1.24] and incident screening -aOR=0.94 [95%CI=0.82-1.08]), cancer detection rate (aOR=0.91 [95%CI=0.69-1.18]), or cancer stages.Conclusions:The COVID-19 pandemic negatively affected screening attendance, especially in previous participants and newcomers. We found no marked differences in recall, false-positives, or cancer detection, indicating the programs resilience. There is a need for further evaluations of interval cancers and potential diagnostic delays. Funding: This study has received funding by grants from Instituto de Salud Carlos III FEDER (grant numbers: PI19/00007 and PI21/00058), and by the Health Outcomes-Oriented Cooperative Research Networks (RICORS) ), with reference RD21/0016/0020 co-funded with European Union - NextGenerationEU funds.

In numerous health systems cancer screening programs were among the first activities 2 interrupted by the COVID-19 pandemic after its irruption in early 2020. As reported in a 3 survey by the International Cancer Screening Network, 97% of participating settings reported 4 that COVID-19 had adversely impacted their screening programs, while 90% partially 5 suspended their activity (1,2). Even in countries with notable success in containing the 6 pandemic, like Taiwan, the population attending screening decreased during the first half of 7 2020 (3). 8 In Europe, breast cancer screening is mostly provided through organized programs offering 9 routine mammography examination to women aged from 45-50 to 69-74 years. The programs 10 follow the guidelines of the European Commission Initiative for Breast Cancer Screening and 11 Diagnosis (4). These guidelines recommend an evidence-based set of performance indicators 12 to evaluate the quality of the screening provision (5) . The suspension of these programs led to 13 a reduction in cancer diagnoses. For instance, in the Netherlands and Austria, the number of 14 breast cancer diagnoses decreased substantially and remained lower than expected until 15 screening was rebooted (6, 7) , while in Italy, between January and May 2020, 53% fewer 16 screens were performed, with a median delay of 2.7-month for screening mammograms (8). 17 Currently, the evidence of the effect of the COVID-19 pandemic on breast cancer screening 18 performance indicators has been mostly provided by simulation models and longitudinal 19 studies are scarce. In Canada, Yong et al. used a mathematical model to estimate that a three-20 month halt would have led to 664,000 fewer screening mammograms than expected, based on 21 nationwide data from the previous year. It would also have decreased breast cancer diagnoses 22 by 7% in 2020 and caused 110 excess deaths by 2029 (9). Similar models in Italy reported 23 that 8,125 breast cancer diagnoses were expected to be delayed due to a three-month 24 interruption of screening programs, representing 25% of the 32,500 yearly screening 25 diagnoses nationwide (10). 26 Spain was one of the first and most affected countries in Europe during the spring of 2020 27 (11,12). On March 14th, a general lockdown was enforced, and breast cancer screening was 28 interrupted (13). Restrictive measures were slowly withdrawn during the following three 29 months until June 21 st , when the lockdown ended (14) . To reintroduce the screening 30 programs as soon as possible while continuing to control the risk of COVID-19 transmission, 31 mammography centers established new safety guidelines (15, 16) . 32 In this before-and-after study, we compared the population-based breast cancer screening 1 indicators obtained in a single population before and after the COVID-19 pandemic. 2 Study population 3 In Spain, publicly funded mammographic screening for breast cancer is offered every two 4 years to women aged 50 to 69 years (17) . The screening examination at PSMAR consists of 5 both a mediolateral oblique and a craniocaudal digital (two-dimensional) mammographic 6 view of each breast. Two independent radiologists with extensive experience perform blinded 7 double reading of mammograms. Disagreements are resolved by a third senior radiologist 8 (18) . The program covers the population of four districts of the city of Barcelona, with 9 around 620,000 inhabitants. Until the current pandemic, screening invitations were sent by 10 postal mail with a pre-scheduled mammography appointment. Since June 2020, previous 11 participants have also received a reminder by telephone.

Invitations are issued during the two-year duration of each screening round according to the We obtained a total of 144,779 observations, from 47,571 eligible women throughout the 10 25 years of study. Each of these observations represented an invitation to the screening program.

In our study population, age group, socioeconomic status, and type of screening round were 27 statistically different in the post-and pre-COVID-19 periods, (Table 1 ). The percentage of 28 invited women living in high-income areas decreased slightly (-1.03%) as did that of women 29 younger than 55 years (-1.83%). The distribution of the type of screening of invited women 30 also changed, with a higher percentage of invitations for prevalent screening (+1.69%), 31 especially first-time invitees (+2.90%). 32 33 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

1 All data from women eligible for screening was obtained from the management database of 2 the program, which is updated yearly with the screening status and baseline characteristics of 3 both participants and non-participants over the years. We completed the information on 4 cancer histology and tumor stages with data the clinical and pathological records. 5 Each screening invitation was considered an independent measurement. All measurements 6 were pseudo-anonymized by using an individual ID for each woman while removing all 7 personal data. Therefore, although multiple measurements per woman could be obtained from 8 invitations in different rounds, all of them shared the same pseudo-anonymized ID. The other three outcomes were analyzed using only the screening participants. The recall rate 25 was estimated as the percentage of participants who were advised to undergo further 26 assessment to rule out malignancy, whether non-invasive or invasive (ultrasound, 27 tomosynthesis, contrast-enhanced mammography, biopsy, and/or others). False positives 28 were estimated based on the percentage of women who underwent additional non-invasive or 29 invasive assessments but who did not have a diagnosis of cancer after completion of 30 additional examinations. The detection rate was the number of breast cancers detected at 31 screening per 1000 participants. We calculated this rate, stratifying by type of breast cancer 32 histology (i.e., the invasive or in situ cancer detection rate). 33 We stratified all the invitations by type of screening between prevalent or incident screening.

Prevalent screening refers to the process of inviting women who have never participated in 35 screening, while incident screening refers to inviting previous participants. In terms of 36 prevalent screening, we differentiated between first-time invitees, and non-participants, 37 referring to previously invited women who had never participated. For incident screening, we 38 differentiated between previous participants who had participated in the previous round 39 (regular participants) and those not participating in the last round (irregular participants).

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 7, 2022. ; https://doi.org/10.1101/2022.03.04.22271911 doi: medRxiv preprint

We categorized women according to their age at the time of invitation in four groups: 50-54, 1 55-59, 60-64, and 65-70 years old. Socio-economic status was estimated with a compound 2 socioeconomic index, created by the Government of Catalonia to assign resources to primary 3 health care, based on the index of each BHA (19). Each woman was assigned the 4 socioeconomic index of the BHA where she was living. Higher values denote a lower 5 socioeconomic level. 6 We evaluated clinical variables such as menopausal status and family history of breast 7 cancer. Breast cancer histology differentiates between in situ and invasive tumors. According Statistical analysis 16 We first compared the characteristics of the invited population among the different screening 17 rounds to describe variations in their distribution. We evaluated differences in the categories 18 using the chi-square test or the exact Fisher test when appropriate.

Then, we created independent logistic regression models to estimate adjusted odds ratios 20 (aOR) of each of the performance indicators and their corresponding 95% confidence 21 intervals (95% CI) for the COVID-19 period, adjusting by the clinically relevant variables.

For participation, we included the following variables in the model: type of screening round 23 (prevalent vs. incident), age group, and socio-economic index. We found a strong interaction 24 between COVID-19 and the type of screening round. Therefore, we created a new variable, 25 which represented this interaction. Hence, the final models for participation differentiated 26 four screening groups (prevalent-first-time invitee, prevalent-previous nonparticipant, 27 incident-regular participant, and incident-irregular participant). We obtained crude results and 28 adjusted by age and socioeconomic index. 29 We created three additional models, including only participants, to assess the impact of Statistical tests were two-sided and all p-values lower than .05 were considered statistically 37 significant.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 7, 2022. ; https://doi.org/10.1101/2022.03.04.22271911 doi: medRxiv preprint SPSS version 25 software was used for the creation and validation of the database and 1 recodification of variables, while statistical software R version 3.5.0 (Development Core 2 Team, 2014) was used for the logistic regression models.

3 Ethical aspects 4 The study guaranteed Spain's legal regulations on data confidentiality (law 15/99 of 5 December 13 on the protection of personal data). Due to the retrospective nature of the study 6 and the absence of direct contact with women, which did not affect their relationship with the 7 program, informed consent was waived by the Ethics Committee of PSMAR, which approved 8 the study (reg.2021/9866). 9

The participation in the program was affected differently depending on the type of screening.

The odds of participating during the post-COVID-19 period were 10% lower (aOR=0.90 95% 12 CI-, 0.84-0.96) for the group of first-time invitees than during the pre-COVID-19 period. The We also found statistically significant differences in the distribution of baseline 1 characteristics of participants during the post-COVID-19 round compared with the mean 2 distributions of the pre-COVID-19 period ( Table 2 ). The percentage of participants younger 3 than 55 years decreased (-1.64%) but the percentage aged between 55 and 59 years increased 4 (+1.73%). The percentage of participants from high socioeconomic level areas slightly 5 decreased (-0.62%). The biggest changes in the distribution of participants were seen between 6 types of screening, with a substantial decrease among participants in the incident screening 7 group (-2.39%) and an increase in the percentage of prevalent screening, especially first-time 8 invitees (+1.96%). The percentage of participants with a family history of breast cancer 9 increased by 2.53%. 1.17) in the prevalent and incident screening groups, respectively (Figure 2) . 7 8 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 7, 2022. ; https://doi.org/10.1101/2022.03.04.22271911 doi: medRxiv preprint When differentiating between cancer histology, we found no statistically significant (Figure 3) . Finally, we observed no statistically significant 4 differences in the distribution of the tumor size, lymphatic invasion, the presence of 5 metastasis or stage at diagnosis between the pre-and post-COVID-19 periods. A statistically 6 non-significant decrease of 4.47% in in-situ tumors, and a non-significant increase of 4.95% 7 in stages I were noted (Table 3) . 8 All crude results did not significantly differ from those adjusted (supplementary file 1). 9 10 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 7, 2022. ; https://doi.org/10.1101/2022.03.04.22271911 doi: medRxiv preprint In this longitudinal study, we found that the pandemic reduced participation, but that this 2 impact differed according to each woman's history of participation. Although attendance was 3 lower during the pandemic period, we found no significant differences in other performance 4 indicators, such as the frequency of recall for additional tests after mammography, the 5 percentage of false-positive results, or the cancer detection rate. 6 Women who became eligible for invitation to our population-based screening program for the 18 Women who had been previously invited but had never attended our screening invitation 19 seemed to participate slightly more during the pandemic period, although this difference was Despite the lower participation, the remaining performance indicators in our program did not 39 seem to be significantly affected by the pandemic. Our results showed a non-statistically 40 significant reduction in the recall rates of both prevalent and incident screening. These 41 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 7, 2022. findings could be due to the increased workload caused by COVID-19 patients at our and 1 many other hospitals, which strongly affected the radiology department in 2020 (27).

Regarding the frequency of false positives, we found no significant variation due to the 3 pandemic, suggesting that the diagnostic accuracy of the radiologists reading the 4 mammograms was not materially affected. Similar pieces of evidence of the resilience of our 5 public health-care system have been recently reported in other hospitals in Barcelona (28), 6 suggesting the strong resilience of health professionals working in critical situations. The 7 COVID-19 pandemic has proved to be a stress test for health care systems around the world 8 and the main elements related to highly effective responses have been associated with 9 adaptation of health systems' capacity, reduction of vulnerability, preservation of health care 10 functions and resources, and activation of comprehensive responses (29). 11 We found no differences in the odds of screen-detected cancer for either prevalent or incident Our study has some limitations. First, we used pseudo-anonymized data and analyzed each 34 invitation as an independent measurement, although a single woman can have more than one 35 invitation. Nevertheless, we considered four groups of type of screening rounds to evaluate 36 attendance, mitigating the fact that the measurements were not truly independent, although 37 this study treated them as though they were. Second, the number of cancers detected during 38 the pandemic period was relatively low, which limited the statistical power of our results.

Our study also has some strengths. To our best knowledge, most of the observational 40 evidence assessing the effect of the pandemic compared screening indicators with the 41 previous year (33-35). In contrast, we included a long period of four previous rounds (eight 42 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 7, 2022. years) of invitations for the same target population. We took this longitudinal approach since 1 it is known that there are fluctuations in participation and cancer detection that may depend 2 on time (36). Therefore, our approach provides information on the pandemic beyond these 3 common fluctuations 4 In conclusion, our findings suggest that the impact of the pandemic on screening attendance 5 depends on the type of screening, with women who regularly participate being the most 6 affected. Targeting this specific population with a proactive invitation could be a way to 7 ensure the historically higher participation in this group. Despite this, we should not forget 8 other groups that attended screening less frequently. Our program has proved to be resilient, CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 7, 2022. 

Early assessment of the first wave of the COVID-19 pandemic on cancer 3 screening services: The International Cancer Screening Network COVID-19 survey

Strengthening the health system response to 6 COVID-19 Recommendations for the WHO European Region Policy brief

COVID-19 pandemic on a population-based breast cancer screening program

European guidelines on 13 breast cancer screening and diagnosis | ECIBC

Monitoring and evaluation of breast cancer screening programmes: Selecting 17 candidate performance indicators

The impact of the temporary suspension of national cancer screening 20 programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal 21 cancer in the Netherlands

Breast cancer 11 screening during covid-19 emergency: Patients and department management in a local 12 experience

Breast 14 imaging and cancer diagnosis during the COVID-19 pandemic: recommendations from 15 the Italian College of Breast Radiologists by SIRM

Descripción del cribado del cáncer en España: Proyecto DESCRIC

Mammographic 22 motivations and intentions about attending for mammography during the COVID-19 1 pandemic

Predictive factors of enrollment and 3 adherence in a breast cancer screening program in Barcelona (Spain)

Factors associated with attendance at screening for breast cancer: a systematic review 7 and meta-analysis

Racial Inequities in Breast Cancer Screening during the COVID-19 Pandemic in 10

Impact of the COVID-19 pandemic on breast cancer screening volumes and 13 patient screening behaviors

Comorbidities 16 and Mortality in Patients With COVID-19 Aged 60 Years and Older in a University 17 Hospital in Spain

Impact of the COVID-19 pandemic on stress, 20 resilience and depression in health professionals: a cross-sectional study

Association of Cancer Screening 1 Deficit in the United States with the COVID-19 Pandemic

COVID-19 state of emergency on breast cancer screening participation in Japan

Breast Cancer

Breast 8 cancer screening in Italy: Evaluating key performance indicators for time trends and